Go to main content
Spain
AOP Health starts Research for Leukemia Treatment
NEWS

AOP Health starts Research for Leukemia Treatment

READ MORE
PULMONARY ARTERIAL HYPERTENSION

"The time taken to establish the correct diagnosis is on average about 14 months."

HematoOncology

"I have two little children and they deserve a good life and a caring mother. That thought gives me strength."

Critical CARE

"We really wish COVID-19 patients would come to the hospital sooner."

Science & Innovation
From the Concept to the Drug

AOP Health team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.

Read More
CONNECTED WORLDWIDE
Partnering

Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease and critical care portfolio and enables to approach patients beyond company’s core markets in Europe.

Read More
Join Us
Join AOP Health

AOP Health team develops and investigates therapy options for patients with rare diseases and in critical conditions – commitment and appreciation are the essence of our cooperative work.

Read More
1
Mag. Andreas Steiner Group CEO AOP Health Group

"AOP Health is unconditionally committed to bringing not only drugs but full treatment support to patients with rare diseases and in critical care."

1
Dr. Gunther Krumpl Board Member AOP Health Group | Founder

"AOP Health having international expertise in pharmaceutical and clinical development as well as distribution and marketing of drugs in the rare disease area offers flexible solutions for in- and out-licensing partnerships."

1
Dr. Rudolf Widmann Board Member AOP Health Group | Founder

"As a company, we are small enough to be really close to our patients, yet we are large enough to be able to provide them high-quality, personalized customer care."